Phospho-TNK2 (Y284) Antibody

What is the biological significance of TNK2 Y284 phosphorylation?

TNK2 (Tyrosine Kinase Non-receptor 2), also known as ACK1 (Activated CDC42 kinase 1), is a tyrosine kinase that plays critical roles in cell signaling. Phosphorylation at Tyrosine 284 (Y284) represents a primary activating site that regulates TNK2 kinase activity . This site has been implicated as crucial for full activation of the kinase domain, with evidence suggesting that Src kinase may phosphorylate this residue .

The phosphorylated form of TNK2 at Y284 shows significant increases in expression during progressive stages of both breast and prostate cancers - from normal tissue to hyperplasia, ductal carcinoma in situ (DCIS), invasive ductal carcinoma (IDC), and lymph node metastatic stages . This progressive increase makes phospho-TNK2 (Y284) a potentially valuable biomarker for cancer progression monitoring.

Recent studies have identified a complex feedback mechanism where TNK2 phosphorylates and activates PTPN11 (SHP2), which in turn deactivates TNK2 through dephosphorylation events . This regulatory circuit appears critical for signal transduction pathways controlling cell growth and differentiation.

What are the recommended applications and optimal dilutions for Phospho-TNK2 (Y284) antibodies?

Phospho-TNK2 (Y284) antibodies have been validated for multiple applications with specific optimal dilution ranges:

It is critical to note that these ranges are guidelines, and optimal dilutions should be determined experimentally for each specific research condition. Factors affecting optimal dilution include tissue type, fixation method, protein abundance, and detection system sensitivity .

How can I verify the specificity of a Phospho-TNK2 (Y284) antibody?

Several methodological approaches can be employed to verify antibody specificity:

• Dot blot analysis: Apply both phosphorylated and non-phosphorylated peptides to a membrane and probe with the antibody. A specific phospho-antibody will recognize only the phosphorylated form .

• Phospho-peptide competition assay: Pre-incubate the antibody with phospho-peptides containing the Y284 site. If specific, this pre-incubation will neutralize the antibody and eliminate signal in subsequent immunoblotting .

• Cross-reactivity testing: Test the antibody against unrelated phospho-peptides (e.g., phospho-AKT, phospho-ATP synthase, phospho-histones). A specific antibody should not cross-react with these unrelated phospho-peptides .

• Phosphatase treatment: Treat cell lysates with a phosphatase inhibitor cocktail. If the antibody is phospho-specific, the signal should significantly increase with phosphatase inhibitor treatment .

• Gene knockout/knockdown verification: Compare signals between wildtype and TNK2-deficient samples. The specific signal should be absent or significantly reduced in knockout/knockdown samples .

• Mutant studies: Express wildtype TNK2 versus TNK2 Y284F mutant (where tyrosine is replaced with phenylalanine, preventing phosphorylation). A phospho-specific antibody should not detect the Y284F mutant .

How does the feedback mechanism between TNK2 and PTPN11 regulate cell signaling pathways?

The TNK2-PTPN11 regulatory circuit represents a sophisticated feedback mechanism controlling signal transduction. Research has revealed the following dynamics:

• Bidirectional regulation: TNK2 phosphorylates PTPN11 at tyrosines 542 and 580, enhancing PTPN11 activation. Activated PTPN11, in turn, dephosphorylates TNK2 at Y284, reducing its activity .

• MAPK pathway modulation: Coexpression of TNK2 and mutant PTPN11 enhances phosphorylation of p44/42 MAPK. This enhancement is further increased with activated TNK2 T205I mutant but abrogated with kinase-inactive TNK2 Y284F mutant .

• Conformational dynamics: When PTPN11 is inhibited using the allosteric inhibitor SHP099, which traps it in a closed, inactive conformation, there is an increase in TNK2 phosphorylation levels in a dose-dependent manner. This confirms that PTPN11 activity is responsible for the reduction in TNK2 phosphorylation .

• Phosphorylation site dependencies: Both Y542 and Y580 in PTPN11 are required for full activation of downstream signaling. Mutation of either residue results in reduction of phospho-p44/42 MAPK to baseline levels .

• Therapeutic implications: This feedback mechanism suggests potential therapeutic strategies targeting either TNK2 kinase activity or PTPN11 phosphatase activity to modulate downstream signaling in disease contexts .

What methods can be used to quantitatively assess TNK2 Y284 phosphorylation dynamics?

Several quantitative approaches can be employed to measure TNK2 phosphorylation dynamics:

• Phospho-specific ELISA: Develop a sandwich ELISA using anti-ACK/TNK2 antibody for capture and phospho-Y284 specific antibody for detection. This allows for quantitative measurement of phosphorylation levels across multiple samples .

• Phospho-flow cytometry: Implement flow cytometry using phospho-specific antibodies to analyze phosphorylation events at the single-cell level, allowing for population heterogeneity assessment.

• Dose-response inhibitor studies: Treat cells with serial dilutions of TNK2 inhibitors (e.g., XMD8-87 or XMD16-5) from approximately 10nM to 5μM and quantify phospho-TNK2 levels. This approach can determine IC50 values for inhibitors and reveal the dynamics of dephosphorylation .

• Time-course studies: Analyze phosphorylation changes over time following stimulation or inhibition to understand the kinetics of phosphorylation/dephosphorylation cycles.

• Quantitative western blotting: Implement standard curves with recombinant phosphorylated proteins and use digital imaging systems to perform densitometric analysis.

• Mass spectrometry: Deploy targeted mass spectrometry approaches such as selected reaction monitoring (SRM) or parallel reaction monitoring (PRM) to quantify phosphopeptides containing the Y284 site.

• Cellular assay systems: Use 293T cells expressing TNK2 in 96-well format (50,000 cells/well) treated with inhibitors for six hours, then analyze using a validated phospho-ELISA approach .

How does TNK2 Y284 phosphorylation influence immune checkpoint regulation?

Recent studies have revealed an unexpected role for TNK2/ACK1 in immune checkpoint regulation:

• CSK phosphorylation: ACK1 phosphorylates C-terminal Src kinase (CSK) at Tyrosine 18 (pY18), which enhances CSK function, thereby constraining T-cell activation .

• T-cell activation regulation: Mice deficient in ACK1 showed reduced CSK Y18 phosphorylation, resulting in decreased LCK Y505 phosphorylation and increased Y394 phosphorylation. This leads to increased phosphorylation of downstream signaling molecules Zap70-Y319, LAT-Y132, and PLCγ-Y783 .

• Mutational analysis: Studies using a CSK-Y18F mutant demonstrated that ACK1-mediated Y18 phosphorylation of CSK is primarily involved in LCK activity regulation. This was shown through coexpression experiments with Myc-tagged LCK and FLAG-tagged CSK or mutant CSK-Y18F with or without HA-tagged ACK1 .

• Therapeutic potential: Inhibiting ACK1-mediated phosphorylation of CSK represents a potential mechanism for reactivating immune responses in cancer therapy, particularly in contexts where solid tumors are highly refractory to immune checkpoint blockade therapies .

• Antibody validation: Antibodies against pY18-CSK were carefully validated using dot blot analysis to ensure they recognized only the CSK peptide with the Y18-phosphorylated residue and not unphosphorylated peptides or unrelated phospho-peptides .

What are the optimal experimental conditions for detecting low levels of phosphorylated TNK2 in clinical samples?

Detecting low-abundance phosphorylated proteins in clinical samples requires optimized experimental conditions:

• Sample preparation:

  • Include phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride, β-glycerophosphate) in all buffers

  • Process samples rapidly at 4°C to minimize dephosphorylation

  • Consider using specialized phosphoprotein enrichment methods prior to analysis

• Western blotting optimization:

  • Use high-sensitivity detection systems (e.g., enhanced chemiluminescence plus or fluorescent secondary antibodies)

  • Employ gradient gels (4-20%) for optimal protein separation

  • Consider longer primary antibody incubation (overnight at 4°C) at higher concentrations (1:250-1:500)

  • Use PVDF membranes rather than nitrocellulose for better protein retention

  • Employ signal enhancement systems (e.g., biotin-streptavidin amplification)

• Immunohistochemistry considerations:

  • Test multiple antigen retrieval methods (heat-induced with citrate or EDTA buffers)

  • Use amplification systems like tyramide signal amplification

  • Consider automated staining platforms for consistency

  • Implement counterstaining strategies that don't interfere with phospho-epitope detection

• Quality control measures:

  • Always include positive controls (e.g., A431 cell lysates treated with phosphatase inhibitors)

  • Implement peptide competition controls to verify signal specificity

  • Consider dual staining with total TNK2 antibody to normalize phospho-signal

• Specialized approaches:

  • Consider proximity ligation assay (PLA) for detecting protein-protein interactions involving phosphorylated TNK2

  • Implement reverse phase protein array (RPPA) for analyzing multiple clinical samples simultaneously

How should samples be prepared to preserve TNK2 phosphorylation status?

Phosphorylation states are notoriously labile, requiring specific handling procedures:

• Lysis buffer composition: Optimal lysis buffer should contain:

  • Complete protease inhibitor cocktail

  • Phosphatase inhibitor cocktail (e.g., PhosSTOP from Roche)

  • Non-denaturing detergent (e.g., Complete Lysis-M EDTA-free from Roche)

  • Buffer pH maintained at 7.4

• Cell lysis protocol:

  • Remove media completely before adding lysis buffer

  • Use approximately 300μl of lysis buffer per well (6-well format) for adherent cells

  • Allow gentle shaking for 5 minutes at room temperature

  • Clear lysates by centrifugation at maximum speed (10 minutes)

• Tissue sample handling:

  • Snap-freeze tissues in liquid nitrogen immediately after collection

  • Process frozen tissue samples using a specialized buffer containing phosphatase inhibitors

  • Consider using pressure cycling technology for difficult-to-lyse tissues

• Post-lysis handling:

  • Keep samples on ice when not being processed

  • Add appropriate loading buffer (e.g., EPage loading buffer with BME)

  • Avoid repeated freeze-thaw cycles by aliquoting samples

What controls should be included when using Phospho-TNK2 (Y284) antibodies in research studies?

Comprehensive control strategies ensure reliable and interpretable results:

• Positive controls:

  • A431 cell lysates (which express detectable levels of phospho-TNK2)

  • 293T cells transfected with TNK2 expression constructs

  • Cells treated with phosphatase inhibitor cocktails

• Negative controls:

  • Samples expressing TNK2 Y284F mutant (non-phosphorylatable)

  • Samples treated with phosphatases to remove phosphorylation

  • TNK2 knockout/knockdown cell lines or tissues

• Specificity controls:

  • Pre-absorption with phospho-peptide containing the Y284 site

  • Pre-absorption with non-phosphorylated peptide (should not affect signal)

  • Unrelated phospho-peptides (e.g., pY37-H2B phospho-peptide)

• Antibody controls:

  • Isotype control antibodies at the same concentration

  • Secondary antibody only (no primary antibody)

  • Use of multiple phospho-specific antibodies from different sources/clones when possible

• Experimental condition controls:

  • Dose-response with TNK2 inhibitors like XMD8-87 or XMD16-5

  • Time-course analysis after stimulation or inhibition

  • Treatment with activators or inhibitors of upstream regulators (e.g., Src inhibitors)

How can phospho-TNK2 antibodies be used to investigate TNK2-dependent signaling in cancer models?

Phospho-TNK2 antibodies enable multiple investigative approaches in cancer research:

• Cancer progression analysis:

  • Immunohistochemical staining of tissue microarrays representing different cancer stages

  • Correlation of phospho-TNK2 levels with clinicopathological parameters

  • Monitoring changes during progression from normal to hyperplasia, DCIS, IDC, and metastatic stages

• Drug response studies:

  • Assessing phospho-TNK2 levels before and after treatment with targeted therapies

  • Combinatorial drug studies targeting TNK2 and related pathways

  • Identification of resistance mechanisms involving TNK2 reactivation

• Signaling network mapping:

  • Co-immunoprecipitation studies to identify phosphorylation-dependent protein interactions

  • Analysis of downstream effectors (e.g., AKT1, AR, WASL, WWOX) following TNK2 activation or inhibition

  • Identification of feedback mechanisms involving PTPN11 and other phosphatases

• Functional studies:

  • Correlation of phospho-TNK2 levels with cell migration, invasion, and proliferation

  • Investigation of TNK2's role in clathrin-mediated endocytosis and EGFR trafficking

  • Analysis of TNK2's interaction with ubiquitin and its contribution to protein degradation pathways

• In vivo models:

  • Analysis of phospho-TNK2 levels in patient-derived xenografts

  • Correlation with response to therapeutic interventions

  • Development of phospho-TNK2-based biomarkers for patient stratification

What are common issues when using Phospho-TNK2 (Y284) antibodies and how can they be resolved?

How can researchers optimize immunoprecipitation protocols using Phospho-TNK2 (Y284) antibodies?

Immunoprecipitation (IP) of phosphorylated proteins requires specific optimization strategies:

• Pre-clearing strategy:

  • Pre-clear lysates with protein A/G beads to reduce non-specific binding

  • Include control IgG antibodies from the same species as the phospho-TNK2 antibody

• Antibody binding optimization:

  • Test various antibody amounts (typically 1-5μg per mg of total protein)

  • Consider crosslinking antibodies to beads to prevent antibody co-elution

  • Determine optimal incubation time (4-16 hours at 4°C with gentle rotation)

• Buffer composition:

  • Use lysis/IP buffers containing phosphatase inhibitors

  • Consider adding 10% glycerol to stabilize protein complexes

  • Adjust NaCl concentration (150-300mM) to balance specificity and sensitivity

• Washing strategy:

  • Implement gradient washing with decreasing salt concentrations

  • Consider mild detergents (0.1% NP-40 or Triton X-100) in wash buffers

  • Perform at least 4-5 washes with buffer rotation between each

• Elution options:

  • For subsequent phosphorylation analysis, consider non-denaturing elution with competing phospho-peptides

  • For maximum recovery, use gentle acid elution (0.1M glycine, pH 2.5)

  • For direct SDS-PAGE analysis, elute directly in sample buffer

• Validation approaches:

  • Perform reverse IP (IP with anti-TNK2 and blot with anti-phosphotyrosine)

  • Include samples treated with phosphatase as negative controls

  • Verify the presence of known TNK2-interacting proteins in the IP samples

How can Phospho-TNK2 (Y284) antibodies contribute to understanding immune checkpoint regulation?

Recent discoveries highlight TNK2's unexpected role in immune regulation, offering new research directions:

• T-cell activation studies:

  • Analyze TNK2 phosphorylation status in resting versus activated T cells

  • Correlate with CSK Y18 phosphorylation and downstream LCK activity

  • Investigate effects on TCR signaling components (Zap70, LAT, PLCγ)

• Immune checkpoint therapy resistance:

  • Evaluate phospho-TNK2 levels in tumor-infiltrating lymphocytes from checkpoint inhibitor responders versus non-responders

  • Investigate combination strategies targeting both TNK2 and established checkpoint molecules

  • Study the relationship between TNK2 activity and T-cell exhaustion markers

• Mechanistic investigations:

  • Map the complete signaling network connecting TNK2 to T-cell function

  • Investigate tissue-specific differences in TNK2-mediated immune regulation

  • Study the impact of tumor-derived factors on TNK2 phosphorylation in immune cells

• Therapeutic development:

  • Screen for compounds that specifically inhibit TNK2-mediated CSK phosphorylation

  • Develop biomarkers to identify patients likely to benefit from TNK2 inhibition

  • Investigate synergies between TNK2 inhibitors and existing immunotherapies

What are the latest methodological advances for studying TNK2 phosphorylation dynamics?

Emerging technologies offer new approaches to studying phosphorylation dynamics:

• Live-cell phosphorylation sensors:

  • Develop FRET-based biosensors incorporating TNK2 phosphorylation sites

  • Implement optogenetic tools to control TNK2 activity with spatial and temporal precision

  • Use fluorescent lifetime imaging microscopy (FLIM) for quantitative phosphorylation measurements

• Single-cell phosphoproteomics:

  • Apply mass cytometry (CyTOF) with phospho-specific antibodies

  • Implement microfluidic platforms for single-cell western blotting

  • Develop spatial proteomics approaches to map phospho-TNK2 distribution within tissues

• Computational modeling:

  • Construct mathematical models of the TNK2-PTPN11 feedback circuit

  • Simulate the effects of perturbations on pathway dynamics

  • Integrate multi-omics data to contextualize phospho-TNK2 signaling networks

• CRISPR-based approaches:

  • Generate phospho-mimetic and phospho-null TNK2 mutations to study functional consequences

  • Use CRISPR activation/inhibition systems to modulate TNK2 expression levels

  • Develop CRISPR-based screens to identify novel regulators of TNK2 phosphorylation